Vanda Pharmaceuticals | VNDA - Equity Capital And Reserves


Vanda Pharmaceuticals reported $327.19M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Akebia Therapeutics USD 32.61M 8.98M Dec/2025
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 568.42M 102.37M Dec/2025
AstraZeneca USD 47.33B 1.33B Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
J&J USD 81.19B 358M Mar/2026
Lexicon Pharmaceuticals USD 107.54M 12.62M Dec/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Moderna USD 7.41B 1.24B Mar/2026
Novartis USD 46.13B 1.8B Dec/2025
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 72.81B 1.1B Mar/2026
Takeda JPY 7.64T 513.39B Dec/2025
Teva Pharmaceutical Industries USD 8.23B 314M Mar/2026
Ultragenyx Pharmaceutical USD -80M 89.16M Dec/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Veracyte USD 1.31B 51.91M Dec/2025